Bioequivalence Study of Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (Pharmtechnology LLC, Belarus), and Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions
PHASE1
This is an open-label, randomized, single-center, single-dose, two-treatmen...
Status
Completed
Location
State Autonomous Healthcare Facility of the Yaroslavl Region "Clinical Hospital No. 2"
Evaluation of the Use of a Probiotic Containing Bifidobacterium Breve PRL2020 in Oral Drops in Preventing Side Effects From Amoxicillin or Amoxicillin/Clavulanic Acid Antibiotic Use
NA
This multicenter, randomized, double-blind, placebo-controlled clinical tri...